Early Access Policy for Investigational Medicines

Orum Therapeutics, Inc. is a biopharmaceutical company leveraging our proprietary platforms for research and development of new pharmaceuticals for cancer and immune diseases with the goal of bringing life-changing therapies to patients. Currently our therapies are investigational, which means that they have not been approved by the United States Food and Drug Administration (FDA) or other Health Authorities. Participation in one of our ongoing trials is the preferred method of obtaining access to one of our investigational new therapies prior to receiving the required regulatory approvals. A listing of our clinical trials can be found on https://clinicaltrials.gov.

We understand that some patients may not be able to participate in a clinical trial. There may be circumstances, particularly later in development, where investigational therapies may be made available to patients via Expanded Access. However, currently, we do not provide our investigational drugs for use through Expanded Access. Instructions for requesting expanded access will be posted on this website if circumstances allow a change to our policy.